Welcome to Multibagg AI
Log in to access personalized features
Discovery themes featuring this stockBearish
8
Neutral
2
Bullish
4
Bearish
8
Neutral
2
Bullish
36
Bearish
0
Neutral
0
Bullish
32
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Innova Captab Limited is an integrated pharmaceutical company engaged in CDMO services, as well as domestic and international branded generics. It operates comprehensive manufacturing units producing various dosage forms across multiple therapeutic areas.
The company has shown a robust financial performance with a 42% YoY revenue growth in Q3 FY26, driven by accelerated expansion in both CDMO and branded generics sectors, particularly with substantial contributions from its Jammu facility.
Innova Captab's manufacturing capabilities are bolstered by recent certifications including UK-MHRA for its Baddi facility and PIC/s for its Jammu facility, aligning with global standards for quality pharmaceuticals production.
The company is strategically focusing on expanding its geographic reach, demonstrated by exports constituting 35% of their revenue in Q3 FY26, showcasing their increasing presence in the global market.
Recent capacity expansions and greenfield projects in Jammu are part of the company's aggressive growth strategy, aiming for increased production capacity and operational scale in the coming years.
Pharmaceuticals & Biotechnology
Pharmaceuticals
5,010 Cr
Low Risk
35.6
34.2
1.0
4.6
1,002.95
608.25
Sales CAGR
Profit CAGR
ROE
ROCE
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Innova Captab Ltd (INNOVACAP) is currently trading at 875.40 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Innova Captab Limited is an integrated pharmaceutical company engaged in CDMO services, as well as domestic and international branded generics. It operates comprehensive manufacturing units producing various dosage forms across multiple therapeutic areas. The company has shown a robust financial performance with a 42% YoY revenue growth in Q3 FY26, driven by accelerated expansion in both CDMO and branded generics sectors, particularly with substantial contributions from its Jammu facility. Innova Captab's manufacturing capabilities are bolstered by recent certifications including UK-MHRA for its Baddi facility and PIC/s for its Jammu facility, aligning with global standards for quality pharmaceuticals production. The company is strategically focusing on expanding its geographic reach, demonstrated by exports constituting 35% of their revenue in Q3 FY26, showcasing their increasing presence in the global market. Recent capacity expansions and greenfield projects in Jammu are part of the company's aggressive growth strategy, aiming for increased production capacity and operational scale in the coming years.
Over the past 52 weeks, Innova Captab Ltd has traded between a low of ₹608.25 and a high of ₹1,002.95. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Innova Captab Ltd has a market capitalization of approximately 5,009.76. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Innova Captab Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 35.55 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 5,009.76 Cr, Innova Captab Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Innova Captab Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Innova Captab Ltd is 35.55. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Investor Presentation
Q4 FY26
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q1 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q1 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
617.80 | 5,697 Cr | 30.75 | 5.27 | 0.14 | 16.86 | 22.47 | 15.40 | ||
138.10 | 5,609 Cr | -20.94 | 0.00 | 0.00 | 77.47 | -181.73 | -83.09 | ||
728.05 | 5,010 Cr | 35.55 | 4.59 | 0.00 | 12.92 | 14.30 | 7.67 | ||
1308.90 | 4,461 Cr | -61.40 | 5.78 | 0.06 | -19.58 | -9.69 | -11.97 | ||
914.00 | 4,451 Cr | 43.81 | 5.47 | 0.00 | 10.70 | 12.41 | 7.98 | ||
333.05 | 4,342 Cr | 90.87 | 16.42 | 0.17 | 18.26 | 19.25 | 12.68 | ||
2453.15 | 4,067 Cr | 35.31 | 6.72 | 0.98 | 19.03 | 24.66 | 14.52 | ||
| Median: 7 Co. | — | 728.05 | 4,461 Cr | 35.31 | 5.47 | 0.06 | 16.86 | 14.30 | 7.98 |
Audited Financial Results
Board approved Audited (Standalone & Consolidated) financial results for quarter and year ended 31 Mar 2026 at meeting on 07 May 2026 and filed the newspaper extract dated 08 May 2026 under Reg.47.
Audited Financial Results
Board of Directors approved Audited (Standalone & Consolidated) financial results for the quarter and year ended 31 Mar 2026; newspaper extract published 08 May 2026 in The Financial Express and The Mumbai Lakshdeep.
Earnings Call Recording
Company posted the audio recording of the analysts/investors earnings call for the audited financial results for the quarter and year ended 31 March 2026 (held 08 May 2026) on its website: www.innovacaptab.com/Audio Recording.
Earnings Presentation
Company submitted an investor presentation for the analysts' earnings call on Q4 & FY26 audited results reporting FY26 revenue ₹1,630.0 Cr (+31% YoY), EBITDA ₹250.3 Cr (15.4%) and PAT ₹140.9 Cr (+9.9%).
Financial Results
Innova Captab announced audited Q4 FY26 and FY26 results: Q4 revenue ₹447.8cr (+42.3% YoY), Q4 EBITDA ₹66.7cr (+30.5%), Q4 PAT ₹38.1cr (+28.8%); FY26 revenue ₹1,630.0cr (+31.1%), FY26 EBITDA ₹250.3cr (+26.3%).
Audited Financial Results
Innova Captab reported audited Q4 FY26 revenue ₹447.8cr (+42.3% YoY), Q4 EBITDA ₹66.7cr and PAT ₹38.1cr; FY26 revenue ₹1,630.0cr (+31.1%), EBITDA ₹250.3cr and PAT ₹140.9cr.
